| Publications | PubMed=3615018
Melodia A., Cornara L., Bertelli R., Canepa M., Gimelli G., Repetto G., Cornaglia-Ferraris P.
New line of human neuroblastoma derived from bone marrow.
Pathologica 78:371-384(1986) PubMed=3204111; DOI=10.1007/BF00398190
Longo L., Christiansen H., Christiansen N.M., Cornaglia-Ferraris P., Lampert F.
N-myc amplification at chromosome band 1p32 in neuroblastoma cells as investigated by in situ hybridization.
J. Cancer Res. Clin. Oncol. 114:636-640(1988) PubMed=3406012
Ponzoni M., Melodia A., Cirillo C., Casalaro A., Cornaglia-Ferraris P.
Effect of cytosine arabinoside on the growth and phenotypic expression of GI-ME-N, a new human neuroblastoma cell line.
Prog. Clin. Biol. Res. 271:437-448(1988) PubMed=3422578; DOI=10.1016/0165-4608(88)90188-4
Donti E., Longo L., Tonini G.P., Verdona G., Melodia A., Lanino E., Cornaglia-Ferraris P.
Cytogenetic and molecular study of two human neuroblastoma cell lines.
Cancer Genet. Cytogenet. 30:225-231(1988) PubMed=2535035; DOI=10.1002/gcc.2870010111
Martinsson T., Weith A., Cziepluch C., Schwab M.
Chromosome 1 deletions in human neuroblastomas: generation and fine mapping of microclones from the distal 1p region.
Genes Chromosomes Cancer 1:67-78(1989) PubMed=2917605; DOI=10.1016/0014-4827(89)90196-1
Ponzoni M., Lanciotti M., Melodia A., Casalaro A., Cornaglia-Ferraris P.
Morphologic and phenotypic changes of human neuroblastoma cells in culture induced by cytosine arabinoside.
Exp. Cell Res. 181:226-237(1989) PubMed=2296463; DOI=10.1203/00006450-199001000-00001
Cornaglia-Ferraris P., Ponzoni M., Montaldo P.G., Mariottini G.L., Donti E., Di Martino D., Tonini G.P.
A new human highly tumorigenic neuroblastoma cell line with undetectable expression of N-myc.
Pediatr. Res. 27:1-6(1990) DOI=10.1016/B978-0-12-333530-2.50006-X
Israel M.A., Thiele C.J.
Tumor cell lines of the peripheral nervous system.
(In book chapter) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.43-78; Academic Press; New York; USA (1994) PubMed=7838528
Cheng N.C., Van Roy N., Chan A., Beitsma M., Westerveld A., Speleman F., Versteeg R.
Deletion mapping in neuroblastoma cell lines suggests two distinct tumor suppressor genes in the 1p35-36 region, only one of which is associated with N-myc amplification.
Oncogene 10:291-297(1995) PubMed=9283597; DOI=10.1016/S0165-4608(96)00362-7
Van Roy N., Jauch A., Van Gele M., Laureys G., Versteeg R., De Paepe A., Cremer T., Speleman F.
Comparative genomic hybridization analysis of human neuroblastomas: detection of distal 1p deletions and further molecular genetic characterization of neuroblastoma cell lines.
Cancer Genet. Cytogenet. 97:135-142(1997) PubMed=9516836; DOI=10.1016/S0959-8049(97)00319-5
Van Roy N., Laureys G., Van Gele M., Opdenakker G., Miura R., van der Drift P., Chan A., Versteeg R., Speleman F.
Analysis of 1;17 translocation breakpoints in neuroblastoma: implications for mapping of neuroblastoma genes.
Eur. J. Cancer 33:1974-1978(1997) DOI=10.1007/0-306-46872-7_2
Thiele C.J.
Neuroblastoma.
(In book chapter) Human cell culture. Vol. 1. Cancer cell lines part 1; Masters J.R.W., Palsson B.O. (eds.); pp.21-53; Kluwer Academic Publishers; New York; USA (1999) PubMed=11550280; DOI=10.1002/gcc.1174
Van Roy N., Van Limbergen H., Vandesompele J., Van Gele M., Poppe B., Salwen H.R., Laureys G., Manoel N., De Paepe A., Speleman F.
Combined M-FISH and CGH analysis allows comprehensive description of genetic alterations in neuroblastoma cell lines.
Genes Chromosomes Cancer 32:126-135(2001) PubMed=17506115; DOI=10.1002/nbm.1181
Peet A.C., McConville C.M., Wilson M.P., Levine B.A., Reed M., Dyer S.A., Edwards E.C., Strachan M.C., McMullan D.J., Wilkes T.M., Grundy R.G.
1H MRS identifies specific metabolite profiles associated with MYCN-amplified and non-amplified tumour subtypes of neuroblastoma cell lines.
NMR Biomed. 20:692-700(2007) PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113
Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010) PubMed=20655465; DOI=10.1016/j.cell.2010.06.004; PMCID=PMC2913027
Holzel M., Huang S.-D., Koster J., Ora I., Lakeman A., Caron H.N., Nijkamp W., Xie J., Callens T., Asgharzadeh S., Seeger R.C., Messiaen L.M., Versteeg R., Bernards R.
NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome.
Cell 142:218-229(2010) PubMed=22213050; DOI=10.1002/ijc.27415; PMCID=PMC3757132
Gawecka J.E., Geerts D., Koster J., Caliva M.J., Sulzmaier F.J., Opoku-Ansah J., Wada R.K., Bachmann A.S., Ramos J.W.
PEA15 impairs cell migration and correlates with clinical features predicting good prognosis in neuroblastoma.
Int. J. Cancer 131:1556-1568(2012) PubMed=24466371; DOI=10.1593/tlo.13544; PMCID=PMC3890703
Loschmann N., Michaelis M., Rothweiler F., Zehner R., Cinatl J., Voges Y., Sharifi M., Riecken K., Meyer J., von Deimling A., Fichtner I., Ghafourian T., Westermann F., Cinatl J. Jr.
Testing of SNS-032 in a panel of human neuroblastoma cell lines with acquired resistance to a broad range of drugs.
Transl. Oncol. 6:685-696(2013) PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016) PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019) PubMed=30971826; DOI=10.1038/s41586-019-1103-9
Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Nature 568:511-516(2019) PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022) |
|---|
